All Stories

  1. Fluticasone furoate, umeclidinium bromide, and vilanterol as a combination therapy for chronic obstructive pulmonary disease

    Article • Expert Review of Respiratory Medicine, November 2018, Taylor & Francis

    Prof. Pierluigi Paggiaro

  2. Nasal Cytology: A Comparative Study of Two Different Techniques of Processing—Smeared versus Cytocentrifuged Slides

    Article • Mediators of Inflammation, November 2018, Hindawi Publishing Corporation

    Andrea Nacci, Prof. Pierluigi Paggiaro

  3. ACTIVATE: the effect of aclidinium/formoterol on hyperinflation, exercise capacity, and physical activity in patients with COPD

    Article • International Journal of Chronic Obstructive Pulmonary Disease, August 2017, Dove Medical Press

    Prof. Pierluigi Paggiaro, Thierry Troosters, Ane Arbillaga

  4. Targeted therapy in severe asthma today: focus on immunoglobulin E

    Article • Drug Design Development and Therapy, June 2017, Dove Medical Press

    Giorgio Walter Canonica, Professor Massimo Triggiani, Prof. Pierluigi Paggiaro

  5. Lung function efficacy and symptomatic benefit of olodaterol once daily delivered via Respimat® versus placebo and formoterol twice daily in patients with GOLD 2–4 COPD: results from two replicate 48-week studies

    Article • International Journal of Chronic Obstructive Pulmonary Disease, July 2014, Taylor & Francis

    Prof. Pierluigi Paggiaro, Alan Hamilton